|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2005-11-23
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The SYNERGY trial comparing enoxaparin and unfractionated heparin in high-risk patients with acute coronary syndromes (ACS) showed that enoxaparin was not inferior to unfractionated heparin in reducing death or nonfatal myocardial infarction (MI) at 30 days.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1538-3598
|
|
pubmed:author |
pubmed-author:AntmanElliottE,
pubmed-author:AylwardPhilip EPE,
pubmed-author:BerdanLisa GLG,
pubmed-author:CaliffRobert MRM,
pubmed-author:CohenMarcM,
pubmed-author:ColJacques JJJ,
pubmed-author:FergusonJames JJJ3rd,
pubmed-author:GargJyotsnaJ,
pubmed-author:GoodmanShaun GSG,
pubmed-author:KleimanNeal SNS,
pubmed-author:LangerAnatolyA,
pubmed-author:MahaffeyKenneth WKW,
pubmed-author:ReistCraig JCJ,
pubmed-author:SYNERGY Trial Investigators,
pubmed-author:WhiteHarvey DHD
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
23
|
|
pubmed:volume |
294
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2594-600
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16304073-Enoxaparin,
pubmed-meshheading:16304073-Fibrinolytic Agents,
pubmed-meshheading:16304073-Follow-Up Studies,
pubmed-meshheading:16304073-Heparin,
pubmed-meshheading:16304073-Humans,
pubmed-meshheading:16304073-Mortality,
pubmed-meshheading:16304073-Myocardial Infarction,
pubmed-meshheading:16304073-Myocardial Ischemia,
pubmed-meshheading:16304073-Myocardial Revascularization,
pubmed-meshheading:16304073-Risk,
pubmed-meshheading:16304073-Stroke,
pubmed-meshheading:16304073-Survival Analysis,
pubmed-meshheading:16304073-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial.
|
|
pubmed:affiliation |
Duke Clinical Research Institute, Durham, NC 27715, USA. mahaf002@mc.duke.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
